Menu Back toAre External Control Arms Ready for Primetime?
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
Are External Control Arms Ready for Primetime?
Zoe Li, MBA
- Director, Life Sciences
- COTA, United States
There are increasing examples of companies submitting real-world data as part of an external control arm. This panel will discuss whether external control arms are really ready for regulatory use and what it will take to achieve broader acceptance.
Learning Objective : Describe how and when to use control arms; Discuss the risks and benefits; Identify the FDA's willingness to accept external comparators in regulatory submissions.
Ravinder Dhawan, PhD
- Vice President, Outcomes Research, Oncology CORE
- Merck & Co., Inc., United States
Leah Burns, MPH
- Group Director, Real World Evidence Strategy
- Bristol-Myers Squibb Company, United States
Aaron Kamauu, MD, MPH, MS
- Managing Director
- Ikaika Health LLC, United States